Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).
1. A method of treating an attention deficit disorder, the method comprising administering a therapeutically effective amount of active agents to a subject in need of treatment of the condition, the active agents comprising droxidopa, or a pharmaceutically acceptable ester, amide, or salt thereof in combination with a DOPA decarboxylase inhibiting compound selected from the group consisting of benserazide, carbidopa, difluoromethyldopa, α-methyldopa, and combinations thereof.
2. The method of claim 1 , wherein the DOPA decarboxylase inhibiting compound is carbidopa.
3. The method of claim 1 , wherein the active agents are administered in one or more pharmaceutical compositions.
4. The method of claim 3 , wherein the active agents are formulated in the same pharmaceutical composition.
5. The method of claim 3 , wherein the droxidopa is administered in a controlled release form.
6. The method of claim 3 , wherein the droxidopa is administered in a sustained release form.
7. The method of claim 1 , wherein the attention deficit disorder is Attention-Deficit/Hyperactivity Disorder (AD/HD).
8. The method of claim 7 , wherein the subject is suffering from at least one symptom of AD/HD, and the method comprises eliminating the symptom, reducing the severity of the symptom, or reducing the frequency of occurrence of the symptom.
9. The method of claim 1 , wherein the droxidopa is administered in a first pharmaceutical composition and the one or more additional active agents are administered in a pharmaceutical composition separate from the droxidopa.
10. The method of claim 1 , wherein droxidopa is administered in the form of a mixture enantiomerically enriched in the L-threo isomer.